These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38443121)

  • 1. Comparing Clinical Outcomes of Steroid-Sparing Therapy With Rituximab Versus Rituximab Alone in Pemphigus.
    Mustin DE; Cole EF; Leibowitz R; Feldman RJ
    J Drugs Dermatol; 2024 Mar; 23(3):e97-e99. PubMed ID: 38443121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience.
    Snast I; Spitzer L; Hodak E; Levi A; Mimouni D; Leshem YA
    Dermatology; 2021; 237(2):179-184. PubMed ID: 32756069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis.
    Agarwal A; Hall RP; Bañez LL; Cardones AR
    PLoS One; 2018; 13(9):e0198074. PubMed ID: 30252855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
    Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
    Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
    Joly P; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Vermeulin T; Benichou J; Musette P;
    Lancet; 2017 May; 389(10083):2031-2040. PubMed ID: 28342637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
    Mignard C; Maho-Vaillant M; Golinski ML; Balayé P; Prost-Squarcioni C; Houivet E; Calbo SB; Labeille B; Picard-Dahan C; Konstantinou MP; Chaby G; Richard MA; Bouaziz JD; Duvert-Lehembre S; Delaporte E; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bédane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Joly P; Hébert V;
    JAMA Dermatol; 2020 May; 156(5):545-552. PubMed ID: 32186656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.
    Tedbirt B; Maho-Vaillant M; Houivet E; Mignard C; Golinski ML; Calbo S; Prost-Squarcioni C; Labeille B; Picard-Dahan C; Chaby G; Richard MA; Tancrede-Bohin E; Duvert-Lehembre S; Delaporte E; Bernard P; Caux F; Alexandre M; Musette P; Ingen-Housz-Oro S; Vabres P; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bédane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Joly P; Hébert V;
    JAMA Dermatol; 2024 Mar; 160(3):290-296. PubMed ID: 38265821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.
    Kushner CJ; Wang S; Tovanabutra N; Tsai DE; Werth VP; Payne AS
    JAMA Dermatol; 2019 Dec; 155(12):1404-1409. PubMed ID: 31642878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.
    Baum S; Gilboa S; Greenberger S; Pavlotsky F; Trau H; Barzilai A
    J Dermatolog Treat; 2013 Dec; 24(6):427-30. PubMed ID: 23521340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: A Review in Pemphigus Vulgaris.
    Frampton JE
    Am J Clin Dermatol; 2020 Feb; 21(1):149-156. PubMed ID: 31838645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study.
    Miše J; Jukić IL; Marinović B
    Front Immunol; 2022; 13():884931. PubMed ID: 35592312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
    Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
    J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus.
    Bozca BC; Bilgiç A; Uzun S
    J Dermatolog Treat; 2022 Jun; 33(4):2102-2109. PubMed ID: 34027788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal involvement is a risk factor for poor clinical outcomes and relapse in patients with pemphigus treated with rituximab.
    Cho SI; Kim JW; Lim JS; Chung JH
    Dermatol Ther; 2019 Mar; 32(2):e12814. PubMed ID: 30623535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early rituximab treatment is associated with increased and sustained remission in pemphigus patients: A retrospective cohort of 99 patients.
    Nosrati A; Mimouni T; Hodak E; Gdalevich M; Oren-Shabtai M; Levi A; Mimouni D; Leshem YA
    Dermatol Ther; 2022 May; 35(5):e15397. PubMed ID: 35194896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable remission of pemphigus with a fixed-dose rituximab protocol.
    Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
    JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
    De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
    Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients.
    Leshem YA; Hodak E; David M; Anhalt GJ; Mimouni D
    J Am Acad Dermatol; 2013 Mar; 68(3):404-11. PubMed ID: 23044076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus.
    Lee MS; Yeh YC; Tu YK; Chan TC
    J Am Acad Dermatol; 2021 Jul; 85(1):176-186. PubMed ID: 32798583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.